Pharmaniaga Berhad Past Earnings Performance
Past criteria checks 0/6
Pharmaniaga Berhad's earnings have been declining at an average annual rate of -32.4%, while the Healthcare industry saw earnings growing at 24.3% annually. Revenues have been growing at an average rate of 6% per year.
Key information
-32.4%
Earnings growth rate
-32.0%
EPS growth rate
Healthcare Industry Growth | 31.5% |
Revenue growth rate | 6.0% |
Return on equity | n/a |
Net Margin | -1.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry
Jul 18Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S
May 09Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 19Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price
Oct 03Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?
Jul 19Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?
Feb 18Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital
Dec 10Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts
Nov 24We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings
Aug 27Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet
May 28Revenue & Expenses Breakdown
How Pharmaniaga Berhad makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 3,479 | -56 | 285 | 0 |
31 Mar 24 | 3,489 | -57 | 297 | 0 |
31 Dec 23 | 3,404 | -80 | 302 | 0 |
30 Sep 23 | 3,507 | -667 | 377 | 0 |
30 Jun 23 | 3,487 | -654 | 300 | 0 |
31 Mar 23 | 3,399 | -655 | 295 | 0 |
31 Dec 22 | 3,481 | -630 | 293 | 0 |
30 Sep 22 | 3,330 | 100 | 224 | 0 |
30 Jun 22 | 4,568 | 164 | 326 | 0 |
31 Mar 22 | 4,984 | 177 | 322 | 0 |
31 Dec 21 | 4,815 | 172 | 306 | 0 |
30 Sep 21 | 4,738 | 80 | 341 | 0 |
30 Jun 21 | 3,230 | 32 | 219 | 0 |
31 Mar 21 | 2,699 | 28 | 205 | 0 |
31 Dec 20 | 2,725 | 27 | 209 | 0 |
30 Sep 20 | 2,806 | -145 | 223 | 0 |
30 Jun 20 | 2,898 | -146 | 231 | 0 |
31 Mar 20 | 2,854 | -146 | 229 | 0 |
31 Dec 19 | 2,821 | -149 | 230 | 0 |
30 Sep 19 | 2,701 | 34 | 211 | 0 |
30 Jun 19 | 2,572 | 48 | 197 | 0 |
31 Mar 19 | 2,553 | 44 | 208 | 0 |
31 Dec 18 | 2,385 | 42 | 205 | 0 |
30 Sep 18 | 2,402 | 60 | 218 | 0 |
30 Jun 18 | 2,388 | 48 | 233 | 0 |
31 Mar 18 | 2,324 | 52 | 222 | 0 |
31 Dec 17 | 2,324 | 54 | 227 | 0 |
30 Sep 17 | 2,294 | 31 | 228 | 0 |
30 Jun 17 | 2,234 | 41 | 231 | 0 |
31 Mar 17 | 2,248 | 46 | 235 | 0 |
31 Dec 16 | 2,189 | 46 | 224 | 0 |
30 Sep 16 | 2,286 | 62 | 229 | 0 |
30 Jun 16 | 2,296 | 69 | 214 | 0 |
31 Mar 16 | 2,277 | 71 | 214 | 0 |
31 Dec 15 | 2,189 | 84 | 212 | 0 |
30 Sep 15 | 2,136 | 105 | 203 | 0 |
30 Jun 15 | 2,114 | 100 | 209 | 0 |
31 Mar 15 | 2,126 | 99 | 205 | 0 |
31 Dec 14 | 2,123 | 94 | 197 | 0 |
30 Sep 14 | 2,064 | 78 | 186 | 0 |
30 Jun 14 | 2,002 | 67 | 176 | 0 |
31 Mar 14 | 1,915 | 57 | 172 | 0 |
31 Dec 13 | 1,947 | 55 | 180 | 0 |
Quality Earnings: PHARMA is currently unprofitable.
Growing Profit Margin: PHARMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHARMA is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare PHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (1.6%).
Return on Equity
High ROE: PHARMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.